PCSA Processa Pharmaceuticals Inc

$PCSA Just checking back in. Is the company still embroiled in that shareholder lawsuit? David, Wendy, George, Russell and Patrick all still getting paid and enriched nearly $2m in compensation after destroying shareholder value 99.8% resulting in a reverse merger where Processa shareholders were left with under 1% of rhe new company. When we getting the readout on 6422 like they promised multiple times while promoting the stock to investors who trusted them based on ambitious promises. Oh yes, there was no readout, they were sued over the drug and had to likwly pay them and give the drug back. Who could have seen it coming? Shocker! Amazing there aren't more shareholder lawsuits here. One of the most egregious and duplicitous things I've personally seen in 25 years of working with and investing in public companies. Nice legacy Dr. David Young.

$PCSA Over the last 5 years, Processa Pharmaceuticals Inc. (PCSA) stock has declined by approximately -99.96%. That is the legacy left by David Young and Patrick Lin. Not sure how either sleep at night knowing what they directly oversaw and did to shareholders. And yet they paid themselves nearly $2M a year on salaries across the management team and made out well in the recent merger transaction leaving existing Processa shareholders with under 1% of the new company. Character counts...

$PCSA Know what you own, who you invested in, and whose getting paid millions despite a 99.8% loss of shareholder value.

$PCSA If you are a shareholder of PCSA I recommend you contact Adam from Bain Capital and ask if he knew the funds from the private placement would go to paying David Young that ran the company into the ground & Patrick Lin who per his facebook account is on vacation 90% of the year. I have already emailed him asking. Shareholders deserve to know.

$PCSA Does anyone know why David Young is still getting paid for running the company into the ground? Do the investors who bought into the private placement like Bain Capital know the funds they put forth are still paying people like David Young? Seems odd. Was it disclosed to them? Maybe they need to be contacted that their money is paying his salary. I bet they would not be happy.

$PCSA 🏥 Processa Pharmaceuticals, Inc. received FDA IND clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria, with additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis.

$PCSA am I understanding the following right? It seems this company plans to get approval for another RS of not less than 1-for-3 and not more than 1-for-9, in their next meeting to be held on Monday, November 30, 2026. Then, they plan to change the company’s name to “Vidya Therapeutics, Inc.” and the common stock will trade on The Nasdaq Capital Market under the symbol “VDYA.” Then, they plan to issue 306,574,202 Shares in addition to some preferred series. These are merger shares when they bought Vidya Therapeutics. I thought these shares were already issued after the last RS. Source: SEC filings from Oct 08, 2026 and Oct 21, 2026.

$PCSA Up 25% today? What gives? These thieves trying to collar more unsupecting retail investors? Looks that way to me. I'll take it because I refuse to sell for a loss. Any chance it hits my avg, 7.46$ before hell freezes over?

$PCSA $NDRA 🔥 today's watchlist — 1 micro/nano-cap + 1 micro/nano-floater covered below. $PCSA (#17) 🚀 strong momentum, ⚠️ elevated risk | Healthcare/Biotechnology ($5.3M) 🔦 Chart flags a recent MACD/Signal crossover — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 Trade policy Export controls Currency fluctuations Regional stability — 📰 Processa Pharmaceuticals Proposes Reverse Stock Split Following Merger with Vidya Therapeutics (Kalkine Media) $NDRA (#10) ⚠️ elevated risk | Healthcare/Diagnostics & Research ($7.7M) — Float 1.4M sh shares 📊 continuation structure characterised by lower highs and lower lows — 🔦 Chart flags a recent test of the reference support level — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 Central-bank policy stance Interest-rate expectations Risk appetite — 📰 187,169 warrant shares are part of ASP Isotopes' stake in ENDRA Life Sciences (NDRA). (Stock Titan)